These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 18440426)
21. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection. Getahun A; Tansuphasawadikul S; Desakorn V; Dhitavat J; Pitisuttithum P J Med Assoc Thai; 2006 Sep; 89(9):1472-8. PubMed ID: 17100387 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Puthanakit T; Oberdorfer A; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V Clin Infect Dis; 2005 Jul; 41(1):100-7. PubMed ID: 15937769 [TBL] [Abstract][Full Text] [Related]
23. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings. Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262 [TBL] [Abstract][Full Text] [Related]
24. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal. Laurent C; Tchatchueng Mbougua JB; Ngom Guèye NF; Etard JF; Diouf A; Landman R; Molinari N; Girard PM; Sow PS; Ndoye I; Delaporte E; Trop Med Int Health; 2011 Feb; 16(2):217-22. PubMed ID: 21087377 [TBL] [Abstract][Full Text] [Related]
25. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD; Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849 [TBL] [Abstract][Full Text] [Related]
26. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
27. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Weidle PJ; Malamba S; Mwebaze R; Sozi C; Rukundo G; Downing R; Hanson D; Ochola D; Mugyenyi P; Mermin J; Samb B; Lackritz E Lancet; 2002 Jul; 360(9326):34-40. PubMed ID: 12114039 [TBL] [Abstract][Full Text] [Related]
28. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir. Abgrall S; Yeni PG; Bouchaud O; Costagliola D; Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827 [TBL] [Abstract][Full Text] [Related]
29. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ; Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704 [TBL] [Abstract][Full Text] [Related]
30. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. ; Keiser O; Tweya H; Boulle A; Braitstein P; Schecter M; Brinkhof MW; Dabis F; Tuboi S; Sprinz E; Pujades-Rodriguez M; Calmy A; Kumarasamy N; Nash D; Jahn A; MacPhail P; Lüthy R; Wood R; Egger M AIDS; 2009 Sep; 23(14):1867-74. PubMed ID: 19531928 [TBL] [Abstract][Full Text] [Related]
31. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less. Bélec L; Bonn JP Future Microbiol; 2011 Nov; 6(11):1251-60. PubMed ID: 22082287 [TBL] [Abstract][Full Text] [Related]
32. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load. Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884 [TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633 [TBL] [Abstract][Full Text] [Related]
38. HIV patients' decision of switching to second-line antiretroviral therapy in India. de Mello-Sampayo F AIDS Care; 2015; 27(7):900-6. PubMed ID: 25723906 [TBL] [Abstract][Full Text] [Related]
39. A model for reduced HIV-1 viral load monitoring in resource-limited settings. Bryant L; Smith N; Keiser P J Int Assoc Provid AIDS Care; 2013; 12(1):67-71. PubMed ID: 22553318 [TBL] [Abstract][Full Text] [Related]
40. Routine CD4 cell count monitoring seldom contributes to clinical decision-making on antiretroviral therapy in virologically suppressed HIV-infected patients. Chow EP; Read TR; Chen MY; Fehler G; Bradshaw CS; Fairley CK HIV Med; 2015 Mar; 16(3):196-200. PubMed ID: 25236189 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]